Monopar Therapeutics (MNPR) Cash & Current Investments (2016 - 2026)

Monopar Therapeutics has reported Cash & Current Investments for 10 years, with the latest figure at $61.8 million in Q4 2025.

• Quarterly Cash & Current Investments rose 34.96% year-over-year to $61.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $61.8 million (up 34.96% YoY) and the FY2025 annual result came in at $61.8 million, up 34.96% from the prior year.
• Cash & Current Investments retreated to $61.8 million in Q4 2025 per MNPR's latest filing, from $127.7 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $127.7 million in Q3 2025 and troughed at $5.5 million in Q3 2023.
• A 5-year average of $25.7 million and a median of $17.1 million in 2022 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2023 and 2025: Cash & Current Investments tumbled 60.39% in 2023, then surged 2020.86% in 2025.
• Over 5 years, Cash & Current Investments stood at $20.0 million in 2021, then plunged by 59.1% to $8.2 million in 2022, then decreased by 11.24% to $7.3 million in 2023, then soared by 530.55% to $45.8 million in 2024, then soared by 34.96% to $61.8 million in 2025.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $61.8 million, $127.7 million, and $39.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.